117 related articles for article (PubMed ID: 28660722)
1. In silico-designed novel non-peptidic ABAD L
Viswanath ANI; Kim T; Jung SY; Lim SM; Pae AN
Chem Biol Drug Des; 2017 Dec; 90(6):1041-1055. PubMed ID: 28660722
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol.
Lim YA; Grimm A; Giese M; Mensah-Nyagan AG; Villafranca JE; Ittner LM; Eckert A; Götz J
PLoS One; 2011; 6(12):e28887. PubMed ID: 22174920
[TBL] [Abstract][Full Text] [Related]
3. Identification of human ABAD inhibitors for rescuing Aβ-mediated mitochondrial dysfunction.
Valaasani KR; Sun Q; Hu G; Li J; Du F; Guo Y; Carlson EA; Gan X; Yan SS
Curr Alzheimer Res; 2014 Feb; 11(2):128-36. PubMed ID: 24479630
[TBL] [Abstract][Full Text] [Related]
4. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction.
Takuma K; Yao J; Huang J; Xu H; Chen X; Luddy J; Trillat AC; Stern DM; Arancio O; Yan SS
FASEB J; 2005 Apr; 19(6):597-8. PubMed ID: 15665036
[TBL] [Abstract][Full Text] [Related]
5. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease.
Lustbader JW; Cirilli M; Lin C; Xu HW; Takuma K; Wang N; Caspersen C; Chen X; Pollak S; Chaney M; Trinchese F; Liu S; Gunn-Moore F; Lue LF; Walker DG; Kuppusamy P; Zewier ZL; Arancio O; Stern D; Yan SS; Wu H
Science; 2004 Apr; 304(5669):448-52. PubMed ID: 15087549
[TBL] [Abstract][Full Text] [Related]
6. ABAD: a potential therapeutic target for Abeta-induced mitochondrial dysfunction in Alzheimer's disease.
Marques AT; Fernandes PA; Ramos MJ
Mini Rev Med Chem; 2009 Jul; 9(8):1002-8. PubMed ID: 19601895
[TBL] [Abstract][Full Text] [Related]
7. Methylene Blue Improves Brain Mitochondrial ABAD Functions and Decreases Aβ in a Neuroinflammatory Alzheimer's Disease Mouse Model.
Zakaria A; Hamdi N; Abdel-Kader RM
Mol Neurobiol; 2016 Mar; 53(2):1220-1228. PubMed ID: 25601181
[TBL] [Abstract][Full Text] [Related]
8. [Mitochondrial enzyme ABAD and its role in the development and treatment of Alzheimer's disease].
Benek O; Musílek K; Kuca K
Ceska Slov Farm; 2012 Aug; 61(4):144-9. PubMed ID: 23251955
[TBL] [Abstract][Full Text] [Related]
9. Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.
Morsy A; Trippier PC
J Med Chem; 2019 May; 62(9):4252-4264. PubMed ID: 30444369
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease.
Yao J; Du H; Yan S; Fang F; Wang C; Lue LF; Guo L; Chen D; Stern DM; Gunn Moore FJ; Xi Chen J; Arancio O; Yan SS
J Neurosci; 2011 Feb; 31(6):2313-20. PubMed ID: 21307267
[TBL] [Abstract][Full Text] [Related]
11. ABAD/17β-HSD10 reduction contributes to the protective mechanism of huperzine a on the cerebral mitochondrial function in APP/PS1 mice.
Xiao X; Chen Q; Zhu X; Wang Y
Neurobiol Aging; 2019 Sep; 81():77-87. PubMed ID: 31252207
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design and synthesis of benzothiazole phosphonate analogues with inhibitors of human ABAD-Aβ for treatment of Alzheimer's disease.
Valasani KR; Hu G; Chaney MO; Yan SS
Chem Biol Drug Des; 2013 Feb; 81(2):238-49. PubMed ID: 23039767
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial β-amyloid in Alzheimer's disease.
Borger E; Aitken L; Muirhead KE; Allen ZE; Ainge JA; Conway SJ; Gunn-Moore FJ
Biochem Soc Trans; 2011 Aug; 39(4):868-73. PubMed ID: 21787315
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.
Hroch L; Benek O; Guest P; Aitken L; Soukup O; Janockova J; Musil K; Dohnal V; Dolezal R; Kuca K; Smith TK; Gunn-Moore F; Musilek K
Bioorg Med Chem Lett; 2016 Aug; 26(15):3675-8. PubMed ID: 27287370
[TBL] [Abstract][Full Text] [Related]
15. Recognition of structurally diverse substrates by type II 3-hydroxyacyl-CoA dehydrogenase (HADH II)/amyloid-beta binding alcohol dehydrogenase (ABAD).
Powell AJ; Read JA; Banfield MJ; Gunn-Moore F; Yan SD; Lustbader J; Stern AR; Stern DM; Brady RL
J Mol Biol; 2000 Oct; 303(2):311-27. PubMed ID: 11023795
[TBL] [Abstract][Full Text] [Related]
16. Surface plasmon resonance and nuclear magnetic resonance studies of ABAD-Abeta interaction.
Yan Y; Liu Y; Sorci M; Belfort G; Lustbader JW; Yan SS; Wang C
Biochemistry; 2007 Feb; 46(7):1724-31. PubMed ID: 17253767
[TBL] [Abstract][Full Text] [Related]
17. Identification of small-molecule inhibitors of the Abeta-ABAD interaction.
Xie Y; Deng S; Chen Z; Yan S; Landry DW
Bioorg Med Chem Lett; 2006 Sep; 16(17):4657-60. PubMed ID: 16781151
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer's disease treatment.
Hroch L; Guest P; Benek O; Soukup O; Janockova J; Dolezal R; Kuca K; Aitken L; Smith TK; Gunn-Moore F; Zala D; Ramsay RR; Musilek K
Bioorg Med Chem; 2017 Feb; 25(3):1143-1152. PubMed ID: 28082069
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction.
Elkamhawy A; Park JE; Hassan AHE; Ra H; Pae AN; Lee J; Park BG; Moon B; Park HM; Roh EJ
Eur J Med Chem; 2017 Mar; 128():56-69. PubMed ID: 28152427
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics.
Kissinger CR; Rejto PA; Pelletier LA; Thomson JA; Showalter RE; Abreo MA; Agree CS; Margosiak S; Meng JJ; Aust RM; Vanderpool D; Li B; Tempczyk-Russell A; Villafranca JE
J Mol Biol; 2004 Sep; 342(3):943-52. PubMed ID: 15342248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]